We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Insulin Manufacturers and PBMs Face Racketeering Charges; Antitrust Allegations Dismissed
Insulin Manufacturers and PBMs Face Racketeering Charges; Antitrust Allegations Dismissed
Drug wholesalers’ claims that Eli Lilly, Sanofi, Novo Nordisk and a group of pharmacy benefit managers (PBMs) engaged in racketeering can proceed, said a federal judge, who at the same time dismissed antitrust allegations that the companies worked together to overcharge for diabetes drugs.